PubMed HealthSearch

Biomedical subjects

J Tashian

Publications and source records attributed to J Tashian.

7 recordsLinked to original sources

Carcinoma of the lung in women.

The 5-year survival of 293 men and of 78 women undergoing pulmonary resection and mediastinal lymph node dissection is compared. These patients were broken into two age groups: Group 1, 40 through 49 years of age, and Group 2, 50 years of age and older. They were subdivided further according to clinical stage, cell type, and sex. Of the 25 men in Group 1, 15 (60%) survived 5 years, while 98 (37%) of the 268 men in Group 2 survived 5 years. Among the 31 women in Group 1, 5 (16%) survived for 5 years, while 15 (32%) of the 47 women in Group 2 survived for that length of time. The survival among women in the younger age group was significantly lower than for both groups of women in the older age group (p = 0.0335) and men in the younger age group (p = 0.0033). This is believed to be due to the higher incidence of both Stage III disease and adenocarcinoma in the younger women. Twenty-two of the younger women (71%) were classified Stage III compared with 14 (30%) of the older women. Fourteen younger men (56%) had reached Stage III, and 101 older men (38%) were classified as Stage III. These data suggest that sex is an important factor in determining survival because there appears to be a relationship between it and the stage of the disease, and cell type. Overall, women had a poorer 5-year survival than men. Younger women have a strikingly lower survival than any other group, which is explained by their higher incidence of both Stage III classification and adenocarcinoma.

Adenocarcinoma

Clinical presentation and management of patients with carcinoma of the lung: a 14-year experience.

Carcinoma of the lung has been steadily increasing since World War II, and the family physician can now expect to see a greater incidence of the disease in women and persons under age 50 years. The clinical manifestations of carcinoma of the lung are described, based on a 14-year experience at the University of Michigan. Diagnostic procedures are outlined. The preferred treatment for carcinoma of the lung is pulmonary resection, combined, in appropriate situations, with mediastinal lymph node irradiation. Survival is dependent to some degree on the tumor cell type as well as the extent of metastasis. A new immunotherapeutic adjunct to resection and irradiation is being developed. Five to ten-year survivors of resections for lung cancer and normal persons serve as lymphocyte donors. Transfer factor is extracted from these lymphocytes and injected into selected patients who have recently had resections for lung cancer. It is too soon to evaluate the results of this experiment, but it is hoped that immunotherapy using transfer factor will be of help to patients with carcinoma of the lung.

Carcinoma, Bronchogenic

Management of unusual traumatic ruptures of the aorta.

Blunt injuries to the ascending aorta and branches of the aortic arch are unusual but must be considered in any victim of a high speed decelerating injury. Because there are no characteristic clinical or roentgenographic findings, aortography is the only definitive method of establishing the diagnosis. Aortography should therefore, be performed upon any patient who has had a high speed decelerating injury, regardless of the clinical or the roentgenographic findings. An early operation will prevent exsanguination.

Adolescent

"Significant".

Explore the source record for details and available documents.

Periodicals as Topic

Carcinoma of the lung: results of treatment over ten years.

Mediastinal lymph node dissection in conjunction with pulmonary resection was performed on 437 patients with bronchogenic carcinoma at the University of Michigan Medical Center from 1959 to 1969. The absolute five- and ten-year survival rates for patients undergoing curative resection were 36.2 and 14.4%, respectively. The five-year survival of those without nodal metastases was 49.3%, and it was 31.1% in patients with hilar metastases only. The five-year survival of patients with mediastinal metastases who received radiation therapy was 23.1%. Of the 193 patients with squamous cell carcinoma, 43% lived five years free from disease. The five-year survival of patients undergoing resection who had no hilar lymph node metastases was 53%, and it was 47.5% in those with hilar metastases only. The five-year survival in patients with mediastinal metastases who received postoperative irradiation was 34.4%.

Adenocarcinoma

Major pulmonary resection for bronchogenic carcinoma in the elderly.

The results of major pulmonary resection in 58 patients greater than 70 years of age were reviewed. The histological distribution and extent of nodal metastases in this age group are the same as in younger patients. The absolute five-year survival rate for the 55 patients undergoing curative resection was 30% (17 patients). It was 36% (11 patients) for those patients with squamous cell carcinoma and 22% (5 patients) for those with adenocarcinoma. The operative mortality was only 14% (8 patients). Of the 49 patients treated by lobectomy, 17 lived five years or more free of disease, whereas none of the 6 patients treated by pneumonectomy survived five years. The five-year survival rate of 30% in this series of elderly patients treated by major pulmonary resection makes resections in such patients with bronchogenic carcinoma worthwhile.

Adenocarcinoma